title: Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells.
abstract: OBJECTIVE
  Nanomedicines represent an alternative for the treatment of aggressive glioblastoma tumors. Behaviour of PLGA-nanoparticles (NPs) was here investigated as a function of their protein adsorption characteristics at the different biological interfaces they are expected to face in order to reach brain cancer cells.
  
  
  METHODS
  NPs were studied for size, zeta potential, blood half-life, in vitro endocytic behavior and in vivo accumulation within healthy rat brain and brain tumors.
  
  
  RESULTS
  While slightly modifying size (80 to 90 nm) and zeta potential (-44 to -32 mV) protein coating of PLGA-NPs by bovine serum albumin (BSA) or transferrin (Tf) greatly prolonged their blood half-life when intravenously injected in rats and mice. In contrast with THP-1 monocytes, differentiated THP-1 macrophages, F98 glioma cells and astrocytes internalized BSA- and Tf-NPs in vitro. Increase of Tf-NP uptake by F98 cells through caveolae- and clathrin-mediated pathways supports specific interaction between Tf and overexpressed Tf-receptor. Finally, in vivo targeting of healthy brain was found higher with Tf-NPs than with BSA-NPs while both NPs entered massively within brain-developed tumors.
  
  
  CONCLUSIONS
  Taken together, those data evidence that Tf-NPs represent an interesting nanomedicine to deliver anticancer drugs to glioma cells through systemic or locoregional strategies at early and late tumor stages.
authors.affiliation: EA 4483, Laboratoire de physiologie, Université de Lille 2, Lille, France.
authors.forename: Jiang
authors.initials: J
authors.lastname: Chang
authors.forename: Archibald
authors.initials: A
authors.lastname: Paillard
authors.forename: Catherine
authors.initials: C
authors.lastname: Passirani
authors.forename: Marie
authors.initials: M
authors.lastname: Morille
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Benoit
authors.forename: Didier
authors.initials: D
authors.lastname: Betbeder
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Garcion
mesh_terms: D000327:Adsorption; D000818:Animals; D001253:Astrocytes / Q000378:metabolism; D001812:Blood-Brain Barrier / Q000378:metabolism*; D001932:Brain Neoplasms / Q000378:metabolism* / Q000473:pathology; D002199:Capillary Permeability; D021941:Caveolae / Q000378:metabolism; D045744:Cell Line, Tumor; D002626:Chemistry, Pharmaceutical; D002966:Clathrin / Q000378:metabolism; D004337:Drug Carriers; D004339:Drug Compounding; D004705:Endocytosis; D005260:Female; D005910:Glioma / Q000378:metabolism* / Q000473:pathology; D006207:Half-Life; D007275:Injections, Intravenous; D019344:Lactic Acid / Q000008:administration & dosage / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics*; D008264:Macrophages / Q000378:metabolism; D051379:Mice; D009000:Monocytes / Q000378:metabolism; D053758:Nanoparticles; D036103:Nanotechnology; D011100:Polyglycolic Acid / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D051381:Rats; D011916:Rats, Inbred F344; D011990:Receptors, Transferrin / Q000378:metabolism; D013678:Technology, Pharmaceutical / Q000379:methods*; D014018:Tissue Distribution; D014168:Transferrin / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*
chemical_list: D002966:Clathrin; D004337:Drug Carriers; D011990:Receptors, Transferrin; D014168:Transferrin; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid